100 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
or death in high-risk
adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial –
– In vitro data indicate … , including hospitalization or death.
Adrienne E. Shapiro, M.D., Ph.D., an infectious disease specialist at Fred Hutchinson Cancer Research Center
S-1
EX-10.3
VIR
Vir Biotechnology Inc
3 Sep 19
IPO registration
4:40pm
in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is not assumed, continued or substituted, (iii) a Change … of your Continuous Service for any reason other than Cause,your Disability or your death (except as otherwise provided in Section 7(d) below);provided
8-K
EX-99.1
VIR
Vir Biotechnology Inc
21 May 21
CORRECTION — EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s
3:38pm
randomized patients, demonstrated an 85% (p=0.002) reduction in hospitalization or death in those receiving sotrovimab compared to placebo … who have progression of COVID-19 as defined by the need for hospitalization for at least 24 hours or death within 29 days of randomization.
The only
S-1/A
EX-10.2
VIR
Vir Biotechnology Inc
30 Sep 19
IPO registration (amended)
6:12am
, by delivering written notice to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death … . In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s estate will be entitled
S-8
EX-4.8
VIR
Vir Biotechnology Inc
15 Oct 19
Registration of securities for employees
4:47pm
, on the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting … from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the Participant’s
8-K
c2z3iywq3yk kkl
28 Jun 21
Other Events
6:07am
S-1
EX-10.2
09x1l0
3 Sep 19
IPO registration
4:40pm
DRS
EX-10.5
ksv4c
27 Jun 19
Draft registration statement
12:00am
S-1
EX-3.3
6rwlnke06cgv8j
3 Sep 19
IPO registration
4:40pm
8-K
a59puot rwe8zogndx8
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
S-1
EX-10.5
n66gtujs
3 Sep 19
IPO registration
4:40pm
DRS
EX-3.3
b7k0veezme
27 Jun 19
Draft registration statement
12:00am
8-K
EX-3.1
qa32tqkj pg2mjx
16 Oct 19
Departure of Directors or Certain Officers
4:01pm
8-K
EX-99.1
1o8dyxe42lpzd
13 Apr 21
Other Events
4:06pm
S-1
EX-10.4
3ti8wdbsr3xyu1x
3 Sep 19
IPO registration
4:40pm
S-1
EX-3.2
qwy48 iwn4lznw
3 Sep 19
IPO registration
4:40pm
8-K
EX-99.2
z62ip ms5zcixq4r
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
sfnjuermh sgydghp6
6 May 21
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2021 Financial Results
4:24pm
8-K
EX-99.1
74t4lq5
5 Aug 21
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
4:14pm